ProKidney Corp. Stock

Equities

PROK

KYG7S53R1049

Biotechnology & Medical Research

End-of-day quote Nasdaq 06:00:00 2024-05-14 pm EDT 5-day change 1st Jan Change
3.92 USD -4.85% Intraday chart for ProKidney Corp. +27.27% +120.22%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * - Sales 2025 * - Capitalization 259M
Net income 2024 * -146M Net income 2025 * -43M EV / Sales 2024 * -
Net cash position 2024 * 178M Net cash position 2025 * 310M EV / Sales 2025 * -
P/E ratio 2024 *
-3.05 x
P/E ratio 2025 *
-5.32 x
Employees 163
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.85%
1 week+27.27%
Current month+89.83%
1 month+92.16%
3 months+161.33%
6 months+122.73%
Current year+120.22%
More quotes
1 week
3.63
Extreme 3.63
4.44
1 month
2.01
Extreme 2.01
4.44
Current year
1.18
Extreme 1.18
4.44
1 year
1.12
Extreme 1.12
13.51
3 years
1.12
Extreme 1.12
14.19
5 years
1.12
Extreme 1.12
14.19
10 years
1.12
Extreme 1.12
14.19
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 23-07-16
Director of Finance/CFO 48 21-12-31
Chief Tech/Sci/R&D Officer 69 19-09-30
Members of the board TitleAgeSince
Director/Board Member 61 21-12-31
Director/Board Member 65 21-12-31
Director/Board Member 60 22-08-10
More insiders
Date Price Change Volume
24-05-20 3.88 -4.32% 1,199,237
24-05-17 4.055 +6.99% 546,776
24-05-16 3.79 -3.32% 412,741
24-05-15 3.92 -4.85% 1,434,217
24-05-14 4.12 +33.77% 2,703,484

End-of-day quote Nasdaq, May 14, 2024

More quotes
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Calendar
2024-05-25 - ERA Congress
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.055 USD
Average target price
4.4 USD
Spread / Average Target
+8.51%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW